Volume 100, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Brett-Major and others remind us that pathogen lists for emerging infectious diseases aid in the development of tools that target specific pathogens (e.g., vaccines) and help attract financial support. These lists tell us what we need to have, not what we need to do. The authors call for more research on ways to prevent these diseases (e.g., platform technologies for vaccines) and mitigate disease impact. Vaccines and new treatments that target individual pathogens have many limitations. However, we might save lives by treating patients with inexpensive generic drugs that target common features of the host response to infection. Undertaking research on this approach to treatment is what we need to do.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Brett-Major DM, Racine T, Kobinger GP, 2019. Consequences of pathogen lists: why some diseases may continue to plague us. Am J Trop Med Hyg 100: 10521055.
    [Google Scholar]
  2. Fedson DS, 2017. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother 14: 790795.
    [Google Scholar]
  3. Wong G, Mendoza EJ, Plummer FA, Gao GF, Kobinger GP, Qiu X, 2018. From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther 18: 159173.
    [Google Scholar]
  4. Plotkin SA, 2017. Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother 13: 27552762.
    [Google Scholar]
  5. Pirofski LA, Casadevall A, 2018. The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases. J Infect Dis 218 (Suppl 1): S7S11.
    [Google Scholar]
  6. Fedson DS, 2016. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med 4: 421.
    [Google Scholar]
  7. Fedson DS, 2018. Influenza, evolution, and the next pandemic. Evol Med Public Health 1: 260269.
    [Google Scholar]
  8. Parihar SP, Guler R, Brombacher F, 2018. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol 19: 104117.
    [Google Scholar]
  9. Binder HJ, Brown I, Ramakrishna BS, Young GP, 2014. Oral rehydration therapy in the second decade of the twenty-first century. Curr Gastroenterol Rep 16: 376.
    [Google Scholar]
  10. Caffrey AR, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V, LaPlante KL, 2017. Evidence to support continuation of statin therapy in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 61: e02228-16.
    [Google Scholar]
  • Received : 28 Jan 2019
  • Accepted : 08 Feb 2019
  • Published online : 18 Mar 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error